In another study of 30 NAFLD patients with elevated liver enzymes, obesity and type 2 DM, exenatide plus insulin was seen to improve steatosis from baseline in 28 (93.3%) patients, which was a significantly higher improvement rate than that observed with intensive insulin therapy24. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.